| 2025-11-17 |
详情>>
内部人交易：
Rubinstein Samuel共交易5笔
|
| 2025-11-14 |
详情>>
股本变动：
变动后总股本588.82万股
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.48美元,归母净利润-631.9万美元,同比去年增长-13.06%
|
| 2025-11-13 |
财报披露：
美东时间 2025-11-13 盘后发布财报
|
| 2025-10-30 |
股东大会：
将于2025-12-10召开股东大会
会议内容 ▼▲
- 1.Elect five director nominees named in this proxy statement;
2.Approve an amendment to our Amended and Restated 2016 Omnibus Incentive Plan (the “2016 Equity Incentive Plan”) to increase the number of shares of common stock reserved for issuance thereunder by 520,000 shares;
3.Ratify the appointment by the Audit Committee of the Board of Directors of CBIZ, CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.Conduct any other business properly brought before the meeting.
|
| 2025-08-28 |
复牌提示：
2025-08-27 15:22:50 停牌，复牌日期 2025-08-27 15:27:50
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-1.18美元,归母净利润-492.1万美元,同比去年增长-41.94%
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.58美元,归母净利润-243.2万美元,同比去年增长27.79%
|
| 2025-03-28 |
详情>>
业绩披露：
2024年年报每股收益-2.65美元,归母净利润-1008.6万美元,同比去年增长6.87%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.52美元,归母净利润-558.9万美元,同比去年增长20.57%
|
| 2024-09-26 |
股东大会：
将于2024-10-29召开股东大会
会议内容 ▼▲
- 1.Elect five director nominees named in this proxy statement;
2.Ratify the appointment by the Audit Committee of the Board of Directors of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.Conduct any other business properly brought before the meeting.
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.99美元,归母净利润-346.7万美元,同比去年增长42.05%
|
| 2024-06-07 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.1美元,归母净利润-336.8万美元,同比去年增长-18.8%
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-0.31美元,归母净利润-1083万美元,同比去年增长-95.17%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.2美元,归母净利润-703.6万美元,同比去年增长-30.56%
|
| 2023-09-25 |
股东大会：
将于2023-10-26召开股东大会
会议内容 ▼▲
- 1.Elect five (5) director nominees named in this proxy statement;
2.Ratify the appointment by the Audit Committee of the Board of Directors of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.Approve an amendment to our existing Certificate of Incorporation (our “Current Charter”) to effect a reverse stock split of our common stock at a reverse stock split ratio not less than 1-for-5 and no greater than 1-for-25, with the exact split ratio, if approved and effected at all, to be set within that range at the discretion of the Board and publicly announced by the Company within 6 months after stockholder approval at the Annual Meeting without further approval or authorization of the Company’s stockholders;
4.An advisory vote to approve the compensation of the Company’s named executive officers;
5.An advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers;
6.Conduct any other business properly brought before the meeting.
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-0.17美元,归母净利润-598.3万美元,同比去年增长-36.16%
|
| 2022-05-18 |
股东大会：
将于2022-06-22召开股东大会
会议内容 ▼▲
- 1.elect seven (7) director nominees named in this proxy statement;
2.ratify the appointment by the Audit Committee of the Board of Directors of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.conduct any other business properly brought before the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-02 |
股东大会：
将于2021-07-07召开股东大会
会议内容 ▼▲
- 1.elect six (6) director nominees named in this proxy statement;
2.approve an amendment to our Amended and Restated 2016 Omnibus Incentive Plan (the “2016 Equity Incentive Plan”) to increase the number of shares of common stock reserved for issuance thereunder by 2,700,000 shares;
3.ratify the appointment by the Audit Committee of the Board of Directors of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.authorize the adjournment of the meeting, if necessary, even if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 2;
5.conduct any other business properly brought before the meeting.
|
| 2020-11-27 |
股东大会：
将于2020-12-30召开股东大会
会议内容 ▼▲
- 1.elect six (6) director nominees named in this proxy statement;
2.approve the amendment to our Fifth Amended and Restated Certificate of Incorporation to include a provision to designate the Delaware Chancery Court as the exclusive forum for certain legal actions;
3.consider an advisory vote to approve the compensation of the Company’s named executive officers;
4.ratify the appointment by the Audit Committee of the Board of Directors of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
5.authorize the adjournment of the meeting, if necessary, even if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 2 and 4;
6.conduct any other business properly brought before the meeting.
|
| 2019-11-27 |
股东大会：
将于2019-12-30召开股东大会
会议内容 ▼▲
- 1.to elect seven directors to serve for the ensuing year and until their successors are elected;
2.to ratify the selection by the Audit Committee of the Board of Directors of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.to conduct any other business properly brought before the meeting.
|
| 2018-11-26 |
股东大会：
将于2018-12-27召开股东大会
会议内容 ▼▲
- 1.to elect seven directors to serve for the ensuing year and until their successors are elected;
2.to ratify the selection by the Audit Committee of the Board of Directors of BDO USA LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to conduct any other business properly brought before the meeting.
|
| 2018-04-27 |
股东大会：
将于2018-05-23召开股东大会
会议内容 ▼▲
- 1.To approve, pursuant to Nasdaq Listing Rules 5635(b) and (d), the issuance of an aggregate of 15,740,742 shares of the Company's common stock pursuant to (i) a Securities Purchase Agreement (the "Accelmed Purchase Agreement") between the Company and Accelmed Growth Partners, L.P. ("Accelmed"), pursuant to which the Company will sell to Accelmed $13.0 million of shares of the Company's common stock at a purchase price of $1.08 per share, (ii) a Securities Purchase Agreement (the "Sabby Purchase Agreement") between the Company and Sabby Management, LLC ("Sabby"), pursuant to which the Company will sell to Sabby $1.0 million of shares of the Company's common stock at a purchase price of $1.08 per share, (iii) a Securities Purchase Agreement (the "Broadfin Purchase Agreement") between the Company and Broadfin Capital LLC ("Broadfin"), pursuant to which the Company will sell to Broadfin $1.0 million of shares of the Company's common stock at a purchase price of $1.08 per share, (iv) Subscription Agreements between the Company and each of Dolev Rafaeli and Gohan Investments, pursuant to which the Company will sell to each of them $1.0 million of shares of the Company's common stock at a purchase price of $1.08 per share (the "Subscription Agreements" and collectively with the Accelmed Purchase Agreement, the Sabby Purchase Agreement and the Broadfin Purchase Agreement, the "Purchase Agreements," and Accelmed, Sabby, Broadfin, Mr. Rafaeli and Gohan Investments, collectively, the "Investors"), plus all additional shares that may be issued pursuant to the Retained Risk Provisions, as defined below, of the Purchase Agreements (the "Transaction") (the "Share Issuance Proposal").
2.To consider and vote upon a proposal to amend the STRATA Skin Sciences, Inc. 2016 Omnibus Incentive Plan to increase the number of shares of the Company's common stock available for grants under the Plan by 3,134,365 shares (the "Amended Plan Proposal").
3.To ratify the decision by our Board of Directors to hold future annual meetings of stockholders as virtual meetings at which stockholders would be able to remotely participate and cast their votes at the meeting in real time (the "Virtual Meeting Proposal").
4.To consider and vote upon a proposal to approve the adjournment of the Special Meeting to solicit additional proxies to vote in favor of Proposals No. 1, No. 2, and No. 3 (the "Adjournment Proposal").
5.To conduct any other business properly brought before the meeting.
|
| 2017-07-27 |
股东大会：
将于2017-09-14召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve for the ensuing year and until their successors are elected;
2.To consider and vote upon a proposal to approve, pursuant to NASDAQ Marketplace Rules, our issuance of up to an aggregate of 15,098,981 shares of our common stock upon the conversion of $40.6 million aggregate principal amount of convertible preferred stock to be issued upon the proposed conversion of our convertible debentures;
3.To consider and cast an advisory vote on a non-binding resolution to approve the compensation of our executive officers disclosed in this Proxy Statement;
4.To consider and cast an advisory vote upon a non-binding resolution to determine the frequency of an advisory vote on executive compensation;
5.To ratify the selection by the audit committee of the Board of Directors of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
6.To consider and vote upon a proposal to approve the adjournment of the Annual Meeting to solicit additional proxies to vote in favor of Proposal No. 2;
7.To conduct any other business properly brought before the meeting.
|
| 2017-04-06 |
详情>>
拆分方案：
每5.0000合并分成1.0000股
|
| 2017-02-17 |
股东大会：
将于2017-03-29召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal to amend the Company's Fifth Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock, par value $0.001 per share, at a specific ratio within a range from 1-for-2 to 1-for-10 and to grant authorization to the Board of Directors to determine, at its discretion, the timing and the specific ratio of the reverse stock split;
2.To consider and vote upon a proposal to approve the adjournment of the Special Meeting to solicit additional proxies to vote in favor of Proposal No. 1.
3.To conduct any other business properly brought before the meeting.
|
| 2016-09-16 |
股东大会：
将于2016-10-27召开股东大会
会议内容 ▼▲
- 1. To elect seven directors to serve for the ensuing year and until their successors are elected;
2. To consider and vote upon a proposal to approve the STRATA Skin Sciences, Inc. 2016 Omnibus Incentive Plan;
3. To ratify the selection by the audit committee of the Board of Directors of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016;
4.To conduct any other business properly brought before the meeting.
|